Summary: We develop a Bayesian nonparametric (BNP) approach to evaluate the effect of treatment in a randomized trial where a nonterminal event may be censored by a terminal event, but not vice versa (i.e., semi-competing risks). Based on the idea of principal stratification, we define a novel estimand for the causal effect of treatment on the non-terminal event. We introduce identification assumptions, indexed by a sensitivity parameter, and show how to draw inference using our BNP approach. We conduct a simulation study and illustrate our methodology using data from a brain cancer trial.
Introduction
Semi-competing risks (Fine et al., 2001 ) occur in studies where observation of a nonterminal event (e.g., progression) may be pre-empted by a terminal event (e.g., death), but not vice versa. In randomized clinical trials to evaluate treatments of life-threatening diseases, patients are often observed for specific types of disease progression and survival. Often, the primary outcome is patient survival, resulting in data analyses focusing on the terminal event using standard survival analysis tools (Ibrahim et al., 2005) . However, there may also be interest in understanding the effect of treatment on nonterminal outcomes such as progression, readmission, etc. An example is a randomized trial for the treatment of malignant brain tumors, where one of the important progression endpoints is based on deterioration of the cerebellum. An important feature of this progression endpoint is that it is biologically plausible that a patient could die without cerebellar deterioration. Thus, analyzing the effect of treatment on progression needs to account for the fact that progression is not well-defined after death. Varadhan et al. (2014) reviews models that have been proposed for analyzing semi-competing data. These models can be classified into two broad categories: models for the distribution of the observable data, e.g., cause-specific hazards, sub-distribution functions (Fix and Neyman, 1951; Hougaard, 1999; Xu et al., 2010; Lee et al., 2015) and models for the distribution of the latent failure times (Robins, 1995a,b; Lin et al., 1996; Wang, 2003; Peng and Fine, 2007; Ding et al., 2009; Peng and Fine, 2012; Chen, 2012; Hsieh and Huang, 2012) . In these approaches, inference has focused on specific model parameters (e.g., regression coefficients).
With the exception of Robins (1995a,b) and more recently Comment et al. (2019) , none of the approaches have discussed causal interpretability of the target parameters. The latter work uses different models (parametric frailty models) and causal assumptions (latent ignorability) than our approach.
In this paper, we are interested in estimating the causal effect of treatment on the nonterminal endpoint from a randomized trial generating semi-competing risk data. Using the potential outcomes framework (Rubin, 1974) , we propose a principal stratification estimand (Frangakis and Rubin, 2002) to quantify the causal effect. We then introduce assumptions that utilize baseline covariates to identify this estimand from the distribution of the observable data and propose a Bayesian nonparametric (BNP) approach for modeling this distribution. An important feature of BNP models is their large support, allowing us to approximate essentially arbitrary distributions (Ishwaran and James, 2001 ). To handle covariates, our approach is based on the dependent Dirichlet process (DDP) prior introduced by MacEachern (1999).
The paper is outlined as follows: Section 2 introduces the motivating brain tumor study.
The formal definition of the causal estimand is introduced in Section 3. We introduce the BNP model in Section 4. A simulation study is summarized in Section 5. We analyze the brain tumor data in Section 6, and conclude with brief discussion in Section 7.
Motivating Brain Tumor Study
The methodology is motivated by a randomized and placebo-controlled phase II trial for 222 recurrent gliomas patients, who were scheduled for tumor resection with recurrent malignant brain tumors (Brem et al., 1995) . Eligible patients had a single focus of tumor in the cerebrum, had a Karnofsky score greater than 60, had completed radiation therapy, had not taken nitrosoureas within 6 weeks of enrollment, and had not had systematic chemotherapy within 4 weeks of enrollment. The data include 11 baseline prognostic measures and a baseline evaluation of cerebellar function. The former includes age, race, Karnofsky performance score, local vs. whole brain radiation, percent of tumor resection, previous use of nitrosoureas, and tumor histology (glioblastoma, anapestic astrocytoma, oligodendrolioma, or other) at implantation. Patients were randomized to receive surgically implanted biodegradable polymer discs with or without 3.85% of carmustine. The follow-up duration was 1 year. Of the 219 patients with complete baseline measures, 204 were observed to die and 100 were observed to progress prior to death. Of the 15 patients who did not die, 4 were observed to have cerebellar progression. Our goal is to estimate the causal effect of treatment on time to cerebellar progression.
Causal Estimand and Identification Assumptions

Potential Outcomes and Causal Estimand
Let The causal estimand of interest is the function
where τ (·) is a smooth function of u. Among patients who survive to time u under both treatments, this estimand contrasts the risk of progression prior to time u for treatment 1 relative to treatment 0. This estimand is an example of a principal stratum causal effect (Frangakis and Rubin, 2002) .
Observed Data
Let Z denote treatment assignment and X denote a vector of the baseline covariates. Let
follows a Gaussian copula model, i.e., Similar assumptions have been used in the causal mediation literature (Daniels et al., 2012) .
Assumption 4: Progression time under treatment z is conditionally independent of death time under treatment 1 − z given death time under treatment z and covariates X = x, i.e.,
Lemma: Under Assumptions 1-4, τ (·) is identified from the distribution of the observed data as follows:
where K(x) is the empirical distribution of X.
Bayesian Regression Model
Dependent Dirichlet Process -Gaussian Process Prior
We start with a review of the Dirichlet process as a prior for an unknown distribution and step by step extend it to the Dependent Dirichlet Process -Gaussian Process prior.
The Dirichlet process (DP) prior has been widely used as a prior model for a random unknown probability distribution. We write H ∼ DP(α, H 0 ) if a random distribution H of a J-dimensional random vector V follows a DP prior, where α is known as the total mass parameter and H 0 is known as the base measure. Sethuraman (1994) provides a constructive definition of a DP, where dH(v) = mass δ θ h (·) with a continuous kernel. For example, a DP mixture of normals takes the form:
is the density function of a multivariate normal random vector with mean vector µ and variance-covariance matrix S.
To introduce a prior on the conditional (on covariates X = x) distribution (H x ) of V , the DP mixture model has been extended to a dependent DP (DDP) by replacing θ h in each term with θ h (x) = {θ h1 (x), . . . , θ hJ (x)}, which is a multivariate stochastic process indexed by x. A DDP mixture of normals takes the form:
To complete the prior specification, we need to posit a stochastic process prior for {θ h (x) :
x}. A common specification are independent Gaussian process (GP) priors (MacEachern, 1999) on {θ hj (x) : x}. A GP prior is specified such that for all L 1 and (
For an extensive review of the GP priors, see Rasmussen and Williams (2006) and MacKay (1999) . We model the mean function µ hj (·) as a linear regression on covariates µ hj (x l ; β hj ) = x l β hj , with covariance process specified as
where D is the dimension of the covariate vector, δ ll = I(l = l ) and is a small constant (e.g., = 0.1) used to ensure that the covariance function is positive definite. To ensure a reasonable covariance structure, continuous covariates should be standardized to have mean 0 and variance 1. More flexible covariance functions can be considered if desired. Additional priors are introduced on the β j 's and Σ, the details of which are discussed in Appendix A1.
We write
Application to Semi-competing Risks Data
Separately for each treatment group z, we posit independent DDP-GP's on the unknown Before transitioning to the posterior sampling algorithm, note that the relevant portion of the observed data likelihood for individual i, with data
We include the second equality because it allows us to see that, using data augmentation to replace the integrals, the joint full data likelihood is
This will allow us to use existing posterior simulation techniques for DDP-GP models.
Posterior Simulation
The details of the MCMC algorithm are presented in Appendix A2. Here we focus on individuals assigned to treatment z and suppress the dependence of the notation on z.
As noted above, the MCMC implementation is based on the full data likelihood. While dH X i is an infinite mixture of normals, we approximate it by a finite mixture with K < ∞ components. This finite mixture model for (Y P i , Y Di ) can be replaced by a hierarchical model where (1) γ i is a latent variable that selects mixture component h (h = 1, . . . , K) with probability w h (properly normalized to handle the finite number of mixture components)
and (2) given γ i , the pair (Y P i , Y Di ) follows a multivariate normal distribution with mean
Posterior simulation is based on this hierarchical model characterization. Importantly, all of the full conditionals in the MCMC algorithm have a closed form representation. Details of the Markov chain Monte Carlo posterior simulation can be found in Appendix A2.
Simulation Studies
Simulation Setup
We considered three simulation scenarios to evaluate the performance of our proposed approach with 500 repeated simulations for each scenario. We generated Z ∼ Bern(0.5).
Independently of Z, we generated two independent covariates X 1 and X 2 , where X 1 followed a truncated normal distribution with mean 4.5, variance 1 and truncation interval (2, 7.5) and X 2 ∼ Bern(0.4). For the first two simulation scenarios, we simulated progression time and death time on the log scale as follows:
In Scenario 1, we assumed ( , ν) followed a bivariate normal distribution with mean (0, 1.5) , marginal variances S 11 = S 22 = 1, and correlation S 12 = 0.75. In Scenario 2, we assumed ( , ν) to be a scaled multivariate t distribution with degree of freedom ν = 3, mean (0, 1.5) , marginal variance S 11 = S 22 = 1, and correlation S 12 = 0.75. Scenario 3 explored performance under a nonlinear covariate effect specification on progression and death times. We generated Y 
for n = 500 independent patients and then coarsened to (Z i , X 1i , X 2i , T i1 , T i2 , δ i , ξ i ).
To explore sensitivity of τ (u) with respect to ρ, we conducted inference for τ (u) under several values of ρ = 0.2, 0.5, 0.8. For all three scenarios, we specified hyperparameters as described in Appendix A1.
For comparative purposes, we implemented a naive Bayesian (Naive) model by assuming that the conditional probability measure (H For each analysis, we ran 5,000 MCMC iterations with an initial burn-in of 2,000 iterations and a thinning factor of 10.
Simulation Results
We first report on the performance in terms of recovering the true treatment-specific marginal survival functions for time to death. For the BNP approach, Figure 1 shows, for each of the three simulation scenarios and by treatment group (first and second rows refer to treatments 0 and 1, respectively), the true survival functions (solid line), the posterior mean survival functions averaged over simulated datasets (dashed line), and 95% pointwise credible intervals (computed using quantiles) averaged over simulated datasets (dotted lines) on the original time scale (days). As another metric of performance, we computed, for each simulated dataset, the root mean squared error (RMSE) taken as the square root of the average of the squared errors at 34 equally-spaced grid points in log-scaled time interval (0, 10). For each scenario, Table 1 summarizes the mean and standard deviation of RMSE across the 500 simulated datasets. Both Figure 1 and Table 1 show that our proposed BNP procedure performs well, for each of the three scenarios, in terms of recovering the true survival function.
[ Figure 1 about here.]
[ Table 2 summarizes the results.
[ Table 2 about here.] Figure 2 showsτ (u) versus u in the three scenarios, respectively, using ρ = 0.2, 0.5 and 0.8. As shown in Figure 2 , in all three scenarios, when ρ = ρ o = 0.5, the estimates under the proposed BNP model reliably recover the simulated true τ (u) and avoid the excessive bias seen with other ρ values. This agrees with the results reported in Table 2 that ρ = 0.5 always yields the smallest mean RMSE in all three scenarios. Furthermore, when ρ = 0.5, the proposed BNP model has smaller mean RMSE compared to the Naive model. When ρ = 0.2 or 0.8, the BNP model performs better or comparable to the Naive model in terms of providing smaller mean RMSE and variability of RMSE across simulations.
[ Figure 2 about here.]
Brain Tumor Data Analysis
An initial analysis of the brain tumor death outcome using Kaplan-Meier is given in Figure   3 , indicating that the treatment group has higher estimated survival probabilities. The estimated difference at 365 days is 2.6% (95% CI: -8.1% to 13.3%). Figure 3 plots the estimated posterior survival curves treatment and control groups with 95% credible intervals; panels (a) and (b) display the results for the BNP and Naive approaches, respectively. Using the BNP approach, the estimated posterior difference in survival at 365 days is 6.2% (95% CI: -1.2% to 13.3%). For the Naive approach, the estimated posterior difference in survival at 365 days is 8.4% (95% CI: 0.2% to 17.9%). The BNP approach produces comparable or higher treatment-specific estimates of survival and greater treatment differences than Kaplan-Meier.
In contrast, the Naive approach produces comparable or lower (higher) estimate of survival for the control (treatment) group than Kaplan-Meier. Comparatively speaking, the Naive approach produces lower treatment-specific posterior estimates of survival than the BNP approach. When we compare the fit to the observed survival data of the BNP and Naive approaches using the log-pseudo marginal likelihood (LPML) (Geisser and Eddy, 1979) , a leave-one-out cross-validation statistic, we see the BNP performs better. Specifically, the LPML for the treatment arm is -144 and -161 for the BNP and Naive approaches, respectively.
The corresponding numbers for the control arm are -137 and -174. we compare the fit to the observed survival and progression data of the BNP and Naive approaches using LPML, we see that the approaches perform comparably. Specifically, the LPML for the treatment arm is -227 and -232 for the BNP and Naive approaches, respectively.
The corresponding numbers for the control arm are -215 and -214.
[ Figure 4 about here.]
Discussion
In this paper, we proposed a causal estimand for characterizing the effect of treatment on progression in a randomized trials with a semi-competing risks data structure. We introduced a set of identification assumptions, indexed by a non-identifiable sensitivity parameter that quantifies the correlation between survival under treatment and survival under control.
Selecting a range of the sensitivity parameter ρ in a specific trial will depend on clinical considerations. For example, in trial of a biomarker targeted therapy, one might expect weaker correlation, since survival under control might be primarily determined by co-morbidities and the survival under treatment might be more determined by the presence of the targeted molecular aberration. In contrast, for some chemotherapies, the same factors that impact survival under control may equally impact survival under treatment, e.g., co-morbidities, social support, etc. Fortunately, the sensitivity parameter is bounded between -1 and 1 and, in most settings, should be positive; a range should be selected in close collaboration with subject matter experts.
We proposed a flexible Bayesian nonparametric approach for modeling the distribution of the observed data. Since the causal estimand is a functional of the distribution of the observed data and ρ, we draw inference about it using posterior summarization. Our procedure can easily be extended to accommodate a prior distribution on ρ, which will allow for integrated inference. Our procedure also allows for posterior inferences about other identified causal contrasts such as the distribution of survival under treatment versus under control. The procedure can also be used for predictive inference for patients with specific covariate profiles. 
A2: MCMC Computational Details
Unless required for clarity, we suppress dependence of the notation on treatment z. Here j is used to denote endpoint (j = 1 for progression and j = 2 for death). We define
(h = 1, . . . , K), X is an n×D matrix where the ith row contains the D-dimensional covariate vector X i for the i-th patient, R j is an n × n matrix where the (i, i ) entry is R j (X i , X i ),
U h is an n h × n matrix where the kth row refers to the kth patient in A h , the ith column refers to patient i and (k, i) element is the indicator that the patient in kth row is the same as the patient in the ith column, I n is an n × n identity matrix,Ỹ hj = {Ỹ ji : γ i = h} where
For z = 0, 1, we iterate through the following 6 updating steps:
(1) Update w h
where
(2) Update α
where v h is generated from step 1.
•
• If δ i = 1 and ξ i = 0
• If δ i = 0 and ξ i = 1
Scenario 1 
